Skip to main content
. Author manuscript; available in PMC: 2010 Dec 29.
Published in final edited form as: Fertil Steril. 2008 Aug 15;92(2):441–447. doi: 10.1016/j.fertnstert.2008.06.054

TABLE 2.

Baseline characteristics during the active phase and placebo hormone phases of the vaginal contraceptive ring cycle.

Variable Active phase 1 Active phase 3 Ring-free phase P value
Blood pressure, mm Hg
 Systolic 113 ± 1.7 114 ± 1.4 115 ± 1.4 .28
 Diastolic 71 ± 1.4 72 ± 1.4 71 ± 1.2 .70
 MAP 86 ± 1.4 85 ± 1.3 86 ± 1.2 .43
Heart rate, beats/min 67 ± 2.0 66 ± 1.6 67 ± 1.5 .77
TC, mg/dL 170.95 ± 9.36 179.63 ± 7.87 170.30 ± 7.15 .06
HDL-C, mg/dL 58.16 ± 3.65 57.15 ± 2.89 58.79 ± 3.64 .68
LDL-C, mg/dL 92.63 ± 6.19a 92.35 ± 5.04a 99.63 ± 5.96 .04
TG, mg/dL 100.26 ± 10.91 108.60 ± 9.65 106.16 ± 13.29 .70
TC/HDL ratio 3.03 ± 0.14 3.05 ± 0.13 3.05 ± 0.255 .97
Endothelin-1, pg/mL 1.16 ± 0.11 1.16 ± 0.10 1.21 ± 0.10 .92
Fibrinogen, mg/dL — 355.32 ± 13.56b 331.86 ± 11.48 .05

Note: Values are in means ± SEM. n=20. P-values indicate the main effects. Fibrinogen samples were only analyzed on Active week 3 and the ring-free phase. HDL-C =high-density lipoprotein cholesterol; LDL-C =low-density lipoprotein cholesterol; MAP =mean arterial pressure; TC =total cholesterol; TG =triglycerides.

a

P=.03 vs. ring-free phase.

b

P=.05 vs. ring-free phase.

Torgrimson. FMD in vaginal contraceptive ring users. Fertil Steril 2009.